Bench to Bedside: Prostate Cancer
Monday 16 July 2007
Venue: The Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE
In the morning, a scientific meeting in the Bench to Bedside series is aimed at urologists, oncologists and research scientists, and will examine cutting edge basic and clinical translational research.
Registration Details:
Fellow: £75
Non-Fellow: £125
Allied Health Professional: £75
Nurse: £75
Retired Fellow: £55
CPD: 3 credits
Useful links
National Cancer Research Institute
NCRI Cancer Conference
Bench to Bedside: Prostate Cancer |
|
9.00 am |
Registration and coffee |
9.25 am |
Welcome Address |
| Dr John Scadding, Dean, RSM | |
|
Session One |
|
| Chair:Mr Ralph Beard, President, RSM Section of Urology | |
9.30 am |
Screening |
| Prof Freddie C Hamdy, Royal Hallamshire Hospital, Sheffield | |
9.55 am |
Localised disease: to treat or not to treat? |
| Dr Christopher C Parker, Royal Marsden Hospital, Sutton | |
10.20 am |
Ablative treatments for prostate cancer: how they might change the way we think about prostate cancer treatment |
| Mr Mark Emberton, University College Hospital | |
10.45 am |
Coffee |
|
Session Two |
|
| Chair:Dr Stephen Harland, University College Hospital, London | |
11.05 am |
How biology produces new treatments |
| Professor Jonathan Waxman, Professor of Oncology, Hammersmith Hospital | |
11.30 am |
Future developments |
| Professor Avigdor Scherz, Weizmann Institute of Science, Israel | |
12.10 pm |
Lunch |
